1
|
Ye F, Li N. Role of p15(INK4B) Methylation in Patients With Myelodysplastic Syndromes: A Systematic Meta-Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2019; 19:e259-e265. [PMID: 31023595 DOI: 10.1016/j.clml.2019.03.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/26/2019] [Accepted: 03/17/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Tumor suppressor gene cyclin-dependent kinase inhibitor 2B (p15(INK4B)) methylation has been frequently reported in myelodysplastic syndromes (MDS). However, the association between p15(INK4B) methylation and MDS remains elusive. Thus, this meta-analysis was first conducted to evaluate the clinical significance of p15(INK4B) methylation in MDS. MATERIALS AND METHODS Eligible studies were identified via an online electronic databases search. The overall odds ratios (ORs) or hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. RESULTS Twenty-eight studies published between 1997 and 2017 were identified, including 1205 MDS patients and 243 nontumor controls. No evidence of heterogeneity was found in our study. p15(INK4B) methylation was significantly elevated in MDS compared with nontumor controls (OR, 10.37; P < .001). In addition, p15(INK4B) methylation was significantly higher in advanced MDS than in early MDS (OR, 4.70; P < .001) and was linked to an unfavorable overall survival (multivariate analysis: HR, 1.78; 95% CI, 1.23-2.71). Subgroup analyses on the basis of ethnicity and detection method showed that the results remained significant in different subgroups (all Ps < .05). CONCLUSION Our findings suggest that p15(INK4B) methylation might play an important role in the development, progression, and poor prognosis of MDS. More prospective studies with larger study populations are needed.
Collapse
Affiliation(s)
- Fang Ye
- Department of Hematology, Chuiyangliu Hospital affiliated to Tsinghua University, Beijing, China.
| | - Ningning Li
- Department of Hematology, Chuiyangliu Hospital affiliated to Tsinghua University, Beijing, China
| |
Collapse
|
2
|
Koga Y, Oba U, Kato W, Ono H, Nakashima K, Takada H. A paediatric case of successful non-myeloablative bone marrow transplantation after azacitidine therapy for non-Down syndrome acute megakaryoblastic leukaemia with monosomy 7. Pediatr Transplant 2016; 20:868-70. [PMID: 27384975 DOI: 10.1111/petr.12739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/18/2016] [Indexed: 12/01/2022]
Abstract
We report a patient with non-Down syndrome AML, also known as AMKL, with monosomy 7, who was also obese and had a hearing impairment and mental retardation. Non-myeloablative bone marrow transplantation was performed successfully after the patient received less aggressive azacitidine treatment, without the usual intensive induction chemotherapy regimen for AML.
Collapse
Affiliation(s)
- Yuhki Koga
- Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Utako Oba
- Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Wakako Kato
- Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Hiroaki Ono
- Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Kentaro Nakashima
- Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Hidetoshi Takada
- Department of Paediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| |
Collapse
|
3
|
Brany D, Dvorska D, Nachajova M, Slavik P, Burjanivova T. Malignant tumors of the uterine corpus: molecular background of their origin. Tumour Biol 2015; 36:6615-21. [DOI: 10.1007/s13277-015-3824-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 07/20/2015] [Indexed: 12/21/2022] Open
|
4
|
Bodoor K, Haddad Y, Alkhateeb A, Al-Abbadi A, Dowairi M, Magableh A, Bsoul N, Ghabkari A. DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. Asian Pac J Cancer Prev 2014; 15:75-84. [PMID: 24528084 DOI: 10.7314/apjcp.2014.15.1.75] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Aberrant DNA methylation of tumor suppressor genes has been reported in all major types of leukemia with potential involvement in the inactivation of regulatory cell cycle and apoptosis genes. However, most of the previous reports did not show the extent of concurrent methylation of multiple genes in the four leukemia types. Here, we analyzed six key genes (p14, p15, p16, p53, DAPK and TMS1) for DNA methylation using methylation specific PCR to analyze peripheral blood of 78 leukemia patients (24 CML, 25 CLL, 12 AML, and 17 ALL) and 24 healthy volunteers. In CML, methylation was detected for p15 (11%), p16 (9%), p53 (23%) and DAPK (23%), in CLL, p14 (25%), p15 (19%), p16 (12%), p53 (17%) and DAPK (36%), in AML, p14 (8%), p15 (45%), p53 (9%) and DAPK (17%) and in ALL, p15 (14%), p16 (8%), and p53 (8%). This study highlighted an essential role of DAPK methylation in chronic leukemia in contrast to p15 methylation in the acute cases, whereas TMS1 hypermethylation was absent in all cases. Furthermore, hypermethylation of multiple genes per patient was observed, with obvious selectiveness in the 9p21 chromosomal region genes (p14, p15 and p16). Interestingly, methylation of p15 increased the risk of methylation in p53, and vice versa, by five folds (p=0.03) indicating possible synergistic epigenetic disruption of different phases of the cell cycle or between the cell cycle and apoptosis. The investigation of multiple relationships between methylated genes might shed light on tumor specific inactivation of the cell cycle and apoptotic pathways.
Collapse
Affiliation(s)
- Khaldon Bodoor
- Department of Biology, Jordan University of Science and Technology, Irbid, Jordan E-mail :
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Matarraz S, Teodosio C, Fernandez C, Albors M, Jara-Acevedo M, López A, Gonzalez-Gonzalez M, Gutierrez ML, Flores-Montero J, Cerveró C, Pizarro-Perea M, Garrastazul MP, Caballero G, Gutierrez O, Mendez GD, González-Silva M, Laranjeira P, Orfao A. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome. PLoS One 2012; 7:e44321. [PMID: 22952954 PMCID: PMC3432128 DOI: 10.1371/journal.pone.0044321] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Accepted: 08/01/2012] [Indexed: 12/22/2022] Open
Abstract
Myelodysplastic syndromes (MDS) are clonal stem cell disorders which frequently show a hypercellular dysplastic bone marrow (BM) associated with inefficient hematopoiesis and peripheral cytopenias due to increased apoptosis and maturation blockades. Currently, little is known about the role of cell proliferation in compensating for the BM failure syndrome and in determining patient outcome. Here, we analyzed the proliferation index (PI) of different compartments of BM hematopoietic cells in 106 MDS patients compared to both normal/reactive BM (n = 94) and acute myeloid leukemia (AML; n = 30 cases) using multiparameter flow cytometry. Our results show abnormally increased overall BM proliferation profiles in MDS which significantly differ between early/low-risk and advanced/high-risk cases. Early/low-risk patients showed increased proliferation of non-lymphoid CD34(+) precursors, maturing neutrophils and nucleated red blood cells (NRBC), while the PI of these compartments of BM precursors progressively fell below normal values towards AML levels in advanced/high-risk MDS. Decreased proliferation of non-lymphoid CD34(+) and NRBC precursors was significantly associated with adverse disease features, shorter overall survival (OS) and transformation to AML, both in the whole series and when low- and high-risk MDS patients were separately considered, the PI of NRBC emerging as the most powerful independent predictor for OS and progression to AML. In conclusion, assessment of the PI of NRBC, and potentially also of other compartments of BM precursors (e.g.: myeloid CD34(+) HPC), could significantly contribute to a better management of MDS.
Collapse
Affiliation(s)
- Sergio Matarraz
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Cristina Teodosio
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Carlos Fernandez
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Manuel Albors
- Servicio de Hematología, Hospital Juan Canalejo, La Coruña, Spain
| | - María Jara-Acevedo
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Antonio López
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - María Gonzalez-Gonzalez
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - María Laura Gutierrez
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Juan Flores-Montero
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Carlos Cerveró
- Servicio de Hematología, Hospital Virgen de la Luz, Cuenca, Spain
| | | | | | | | - Oliver Gutierrez
- Servicio de Hematología, Hospital Rio Hortega, Valladolid, Spain
| | - Guy Daniel Mendez
- Servicio de Hematología, Hospital de Jerez de la Frontera, Cádiz, Spain
| | | | - Paula Laranjeira
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Alberto Orfao
- Centro de Investigación del Cáncer (Instituto de Biología Celular y Molecular del Cáncer, CSIC-USAL), IBSAL, Servicio de Citometría and Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
- * E-mail:
| |
Collapse
|
6
|
Engel N, Rank A. Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics 2011; 3:611-23. [DOI: 10.2217/epi.11.80] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Allogeneic hematopoietic stem cell transplantation is a high risk but curative treatment option for leukemia, myelodysplasia and other hematological malignancies. After high dose radio- or chemo-therapy, recipient’s hematopoiesis is replaced by a new immunosystem and residual malignant cells are eliminated by the graft-versus-leukemia reaction. The benefit of this immunological effect is limited by the most frequent complication of hematopoietic stem cell transplantation: graft-versus-host disease. In addition to their well-known anti-tumor activity, epigenetic drugs mediate immunotolerance without reducing alloreactivity or even enhance graft-versus-leukemia effect without inducing graft-versus-host disease by regulating cytokine release, increasing the circulating number of regulatory T cells and interacting with natural killer cells. We focus on the use of epigenetic drugs in the allogeneic transplantation setting in relation to their anti-tumor and immunomodulatory potential.
Collapse
Affiliation(s)
- Nicole Engel
- Ludwig-Maximilians-University Munich (Munich, DE), Großhadern Medical Center, Medical Department III, Germany
| | - Andreas Rank
- Klinikum Augsburg (Augsburg, DE), Medical Department II, Germany
| |
Collapse
|
7
|
Musolino C, Sant’Antonio E, Penna G, Alonci A, Russo S, Granata A, Allegra A. Epigenetic therapy in myelodysplastic syndromes. Eur J Haematol 2010; 84:463-73. [DOI: 10.1111/j.1600-0609.2010.01433.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
8
|
Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, Dipersio JF, Vij R. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 2009; 84:560-4. [PMID: 19650118 DOI: 10.1002/ajh.21482] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The approved 7-day schedule of subcutaneous azacitidine for myelodysplastic syndrome is associated with injection site reactions and bruising and may be inconvenient because of the need for weekend doses. Although pharmacokinetic data with IV azacitidine suggests equivalence, there are no efficacy data published. Patients with all myelodysplastic syndromes (MDS) FAB subtypes were enrolled and received 75 mg/m(2)/d of azacitidine by 20-min intravenous infusion for 5 days in every 28 days. Global methylation studies were performed at baseline and prior to Cycle 3. Twenty-five patients were enrolled and 22 were evaluable. Median age was 69.5 years; 9 (41%) patients had lower-risk disease (IPSS Low or Int-1) and 13 (59%) had higher-risk disease (IPSS Int-2 or High). Twenty-seven percent of patients responded (5 CRs and 1 PR). The median time to response was 108 days. The median PFS was 339 days (11.3 months), the median OS was 444 days (14.8 months) and the median duration of response (DOR) was 450 days (15.0 months). Global methylation studies suggest a greater degree of demethylation in responders. This regimen appeared to offer a PR + CR rate and median DOR somewhat similar to what has been reported with the 7-day subcutaneous regimen; however, OS was shorter.
Collapse
Affiliation(s)
- Mike G Martin
- Washington University School of Medicine, Saint Louis, Missouri 63110, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Quesnel B. Methyltransferases in myelodysplastic syndromes: Guilty or not guilty? Leuk Res 2009; 33:601-2. [DOI: 10.1016/j.leukres.2008.11.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2008] [Revised: 11/03/2008] [Accepted: 11/06/2008] [Indexed: 10/21/2022]
|
10
|
Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol 2007; 35:394-406. [PMID: 17309820 DOI: 10.1016/j.exphem.2006.11.005] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2006] [Revised: 11/06/2006] [Accepted: 11/08/2006] [Indexed: 11/16/2022]
Abstract
OBJECTIVE The tumor suppressor p15Ink4b (Ink4b) is a cell-cycle inhibitor that is inactivated in a high percentage of acute myeloid leukemia and myeloid dysplasia syndrome cases. Despite this, the role of Ink4b in hematopoiesis remains unclear. Here we examined the role of Ink4b in blood cell formation using Ink4b-deficient (Ink4b(-/-)) mice. METHODS We compared the bone marrow (BM) of Ink4b(-/-) and wild-type mice using flow cytometric, colony-forming unit and competitive repopulating assays (CRA). The proliferation, differentiation, self-renewal, and apoptosis of progenitor cells were further compared by in vitro and in vivo methods. RESULTS BM from Ink4b(-/-) mice contained increased numbers of granulocyte-monocyte progenitors and Gr-1(+) cells and showed a competitive advantage over wild-type cells in myeloid cell formation by CRA. Ink4b(-/-) progenitors did not demonstrate increased proliferation, self-renewing potential, or reduced apoptosis. Instead, Ink4b(-/-) common myeloid progenitors (CMPs) showed increased myeloid progenitor formation concomitant with reduced erythroid potential. CONCLUSIONS This work establishes a role for Ink4b in regulating the differentiation of CMPs and indicates that loss of Ink4b enhances the formation of myeloid progenitors.
Collapse
Affiliation(s)
- Michael Rosu-Myles
- Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892-4263, USA
| | | | | |
Collapse
|
11
|
Quesnel B. Methylation and myelodysplastic syndromes: When and where? Leuk Res 2006; 30:1327-9. [PMID: 16781771 DOI: 10.1016/j.leukres.2006.05.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2006] [Revised: 05/03/2006] [Accepted: 05/05/2006] [Indexed: 11/18/2022]
|
12
|
Flohr H, Breull W. Effect of etafenone on total and regional myocardial blood flow. Semin Hematol 1976; 50:16-37. [PMID: 23 DOI: 10.1053/j.seminhematol.2013.01.001] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The distribution of blood flow to the subendocardial, medium and subepicardial layers of the left ventricular free wall was studied in anaesthetized dogs under normoxic (A), hypoxic (B) conditions and under pharmacologically induced (etafenone) coronary vasodilation (C). Regional myocardial blood flow was determined by means of the particle distribution method. In normoxia a transmural gradient of flow was observed, with the subendocardial layers receiving a significantly higher flow rate compared with the subepicardial layers. In hypoxia induced vasodilation this transmural gradient of flow was persistent. In contrast a marked redistribution of regional flow was observed under pharmacologically induced vasodilation. The transmural gradient decreased. In contrast to some findings these experiments demonstrate that a considerable vasodilatory capacity exists in all layers of the myocardium and can be utilized by drugs. The differences observed for the intramural distribution pattern of flow under hypoxia and drug induced vasodilation support the hypothesis that this pattern reflects corresponding gradients of regional myocardial metabolism.
Collapse
|